Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical trial assessing HB700

Next Previous
X
Search
Trial Profile

A phase I clinical trial assessing HB700

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB 700 (Primary)
  • Indications Colon cancer; Colorectal cancer; Lung cancer; Pancreatic cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 02 Jan 2025 According to a Hookipa Pharma media release, interim data expected in the first half of 2026.
    • 24 Apr 2024 According to a Hookipa Pharma media release, company received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700.
    • 29 Jan 2024 According to HOOKIPA media release, the company plans to submit an IND for HB-700 in the first quarter of 2024 and will begin searching for a collaboration partner.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top